Skip to content
Catalyst

PapersPMID:38563131

Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.

Skin research and technology2024The record ↗

  1. Finding, moderate evidenceno difference foundPsoriasis Area and Severity Index (PASI) score

No finding here moved its endpoint.

What did not

1 findingHow to read these marks →
  • “Although the PASI score in the melatonin and rosuvastatin groups compared with placebo decreased, the changes were not significant.”
    Study
    RCT
    Dose studied
    melatonin cream 5.0% (w/w) applied twice a day
    Population
    adults with mild-to-moderate plaque psoriasis; melatonin cream 5% w/w vs placebo cream, applied twice daily for 8 weeks

Study record

Design
randomised controlled trial
Species
human
Population
Adults with mild to moderate stable plaque psoriasis (lesion area ≤100 cm2).
Participants
77
Comparator
an active treatment / placebo
Duration
60 days
Endpoints measured
21